The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approving an oral therapy to treat
myelofibrosis patients with moderate to severe anaemia.
Myelofibrosis is a rare blood cancer that affects the body's normal production of blood cells, and the affected patients are likely to develop anaemia over the
course of the disease.
British drugmaker GSK, the manufacturer of the oral therapy known as momelotinib, said that it can be used to treat "both newly diagnosed and previously treated
myelofibrosis patients."
The medicine helps address disease-related splenomegaly (enlarged spleen) or symptoms in adult patients who are Janus kinase (JAK) inhibitor naïve or have been
treated with ruxolitinib, as stated by the company.
Nina Mojas, Senior Vice President of Oncology Global Product Strategy at GSK, said that receiving the positive CHMP opinion "is a significant step in bringing
momelotinib to patients in the EU with this difficult-to-treat blood cancer."
One in eight people who were hospitalised with Covid-19 between May 2020 and March 2021 were later diagnosed with myocarditis, according to major new research
into the clinical long-term effects of coronavirus.
The largest study of its kind to date was led by the University of Glasgow in collaboration with NHS Greater Glasgow and Clyde (NHS GGC), and followed for one year, in real time, 159 patients after they were hospitalised with Covid-19.
The study also looked at why some patients suffer long-term ill health after hospitalisation with Covid-19. Until now it has been speculated that previous underlying
health conditions may be linked to the severity of post-Covid long-term effects.
However, this new study suggests that it is the severity of the infection itself which is most closely correlated to the severity of a patient's long-Covid symptoms, rather than pre-existing health problems.
Hospitalisation with Covid-19 was found to cause a number of long-term health problems.
Researchers found one in eight patients hospitalised with Covid-19 have heart inflammation, while inflammation across the body and damage to the other organs such as the kidneys was also common.
UK regulator has approved a second oral antiviral for early treatment of Covid-19 in high-risk adults, after molnupiravir.
The Medicines and Healthcare products Regulatory Agency (MHRA) gave its nod for a new treatment called Paxlovid (PF-07321332 and ritonavir), after finding it safe and effective at reducing the risk of hospitalisation and death in people diagnosed with mild Covid-19 infection.
Developed by Pfizer, Paxlovid prevents the multiplying of virus, helping the body to overcome the infection.
A clinical trial for the treatment in high risk individuals revealed that a five-days course of Paxlovid reduces the risk of hospitalisation and death by 89 per cent.
It further revealed that Paxlovid is most effective when taken in the early stage of infection.
Dr June Raine, MHRA chief executive, said: "We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered
intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage."
A person in England has been diagnosed with a rare viral monkeypox infection thought to be linked to travel to West Africa, health authorities said at the weekend (May 7).
The UK Health Security Agency (UKHSA) said in a statement the case, in a person who had recently traveled to Nigeria, was being treated at an expert respiratory infectious disease unit at Guy's and St Thomas' NHS Foundation Trust in London.
"It is important to emphasise that monkeypox does not spread easily between people and the overall risk to the general public is very low," said Colin Brown, director of clinical and emerging infections at UKHSA.
The UK Health Security Agency (UKHSA) has advised self-isolation for people diagnosed with monkeypox to reduce the risk of spreading the infection.
Household members are at the highest risk of becoming infected from a case within their house. The new guidance advises people with monkeypox infection to take steps to try and limit transmission within the household.
"Monkeypox infection mainly spreads between people through direct, skin-to-skin contact, including sexual contact. Infection can also be spread via contaminated
objects such as linen and soft furnishings," said UKHSA.
The guidance advises that, where possible, cases are encouraged to sleep and eat in a separate room and use a separate bathroom to their household if possible. Good hygiene measures, to follow at all times, have also been set out.
It suggests, "Where the use of a separate room isn't possible, cases should avoid physical contact and keep at least three steps (one metre) away from all household
members. It is particularly important that they avoid close contact with young children, pregnant women and immunosuppressed people as they may be at higher risk of serious illness."
Statistics show that 1 in 8 women will develop breast cancer at some point in their lives. While this disease can be deadly, it is also preventable. This
blog post will discuss six things you need to know about breast cancer prevention. Knowledge is power when it comes to fighting cancer, so read on and learn how
you can protect yourself.
UNDERGO ROUTINE CHECKUPS
One of the first things you can do to prevent breast cancer is to undergo routine checkups. This means going for mammograms and clinical breast exams regularly. In
this case, your doctor may even recommend using ultrasound technology to get a clear picture of the breast tissue. Rest assured that your doctor will be able to
detect any changes in your breasts and will be able to determine if there is anything to worry about. The earlier you catch any abnormalities, the better your chances
of beating cancer.
BE AWARE OF YOUR FAMILY HISTORY
Another important factor to consider is your family history. If you have close relatives who have been diagnosed with breast cancer, your risk may be higher. This is
because some forms of breast cancer can be hereditary. As such, it is important to be aware of your family history and to let your doctor know if there is a history
of breast cancer in your family. From there, you should discuss your options with your doctor and make sure to get regular screenings. More often than not, early
detection is key when it comes to surviving breast cancer which is why family history is so important.
If your loved one is suffering from anxiety, you'll likely be aware of how damaging the condition can be. Anxiety comes in many forms and can be triggered by
an array of factors, but there are some simple steps to take if you want to improve the wellbeing of your family member - how can you best go about supporting a
loved one with anxiety?
What is anxiety? - Anxiety is mental state in which we feel highly worried, nervous, uneasy, or uncomfortable. While it's normal to feel anxious in certain situations
and at notable points in our lives (this is linked to the 'fight or flight' instinct), it's important to address the problem if you feel that your anxiety is
impacting your quality of life.
What are the five major forms of anxiety? - The 5 most common forms of anxiety as diagnosed by medical professionals include generalised anxiety disorder,
obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder and social phobia, also known as anxiety disorder.
What causes anxiety problems? - Anxiety can be caused by a wide range of factors. We're more likely to become anxious when we're overworked, stressed, depressed,
under financial pressure or physically or mentally unwell. It's also common to become anxious after traumatic events such as having to make medical negligence claim
after sustaining a surgical based injury, losing a home or the death of a loved one.
Esperion Therapeutics' non-statin therapy "bempedoic acid" has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant
patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial, revealed GlobalData, a leading data and analytics company.
As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in near-term based on these results, said
GlobalData.
According to GlobalData's Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in Australia is expected to increase at
a compound annual growth rate of approximately 1.2% from 5.2 million in 2022 to 5.4 million in 2025.
Neha Myneni, Pharma Analyst at GlobalData, comments: "Bempedoic acid joins several statin alternatives that have shown the potential to reduce cardiac illnesses.
However, with not much significant improvement in the outcomes, there exists a clear room for improvement for non-statin therapies in this space."
Bempedoic acid is the sixth class of cholesterol-lowering drugs (other than cholesteryl-ester transfer protein isoform (CETPi) inhibitors), that has demonstrated the
potential to reduce heart attacks and strokes. Other class of therapies with similar potential currently marketed in Australia include statins, bile acid resins,
niacin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab, and inclisiran).
AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with
advanced ovarian cancer.
The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free
survival in newly diagnosed patients with advanced ovarian cancer without certain mutations.
Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with
chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added.
Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial,
said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for
the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community."
Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an
unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour
BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary
endpoints as well as data for relevant subgroups."
Endocrinology is the study of hormones and glands in the human body. The endocrine system produces and secretes hormones that regulate many bodily functions,
including growth and development, metabolism, and reproductive health. Endocrinologists are physicians who specialize in diagnosing and treating hormonal imbalances
and disorders. There are several reasons why you might consider seeing an endocrinologist. In this article, we'll explore some of the most common reasons people seek
out the expertise of an endocrinologist.
YOU HAVE DIABETES
If you have diabetes, it is important to consider seeing an endocrinologist. Endocrinologists specialize in managing diabetes and can help you develop a personalized
treatment plan to manage your blood sugar levels. They can also help you prevent or manage complications of diabetes, such as nerve damage, kidney disease, and eye
problems. An endocrinologist can work with you to develop a healthy lifestyle plan that includes diet, exercise, and medication management.
They can also help you adjust your treatment plan as needed to ensure that your diabetes is well-controlled. Seeing an endocrinologist can help you achieve better
health outcomes and improve your overall quality of life.
The UK government's community diagnostic centre programme, which was first launch in July 2021, is helping cut waiting lists, and speed up diagnoses and
treatments for NHS patients.
As of November 2023, a total of 6.1 million vital checks have been carried out at community diagnostic centres (CDCs) across England, according to a joint statement
released by the Department of Health and Social Care (DHSC) and NHS England.
Under the £2.3 billion programme, 141 CDCs have been opened across the country in a variety of settings including shopping centres, university campuses and football
stadiums, offering patients a wide range of diagnostic tests closer to home.
The government has set a target to open 160 CDCs by March 2025, with many expected to open ahead of schedule.
The Medicine and Healthcare products Regulatory Agency (MHRA) has cautioned men on valproate to talk to their healthcare professional about their treatment,
if they want to start a family in the next year.
The warning came after a new study, commissioned by the European Medicines Agency, suggested that children fathered by men who took the anti-seizure medicine in
the three months prior to conception may be at higher risk of developing neurodevelopmental disorders.
Around five in 100 children born to fathers treated with valproate around conception were diagnosed with a neurodevelopmental disorder, compared to three in
100 children whose fathers were taking other antiseizure medicines (lamotrigine or levetiracetam).
However, the risk is believed to be much smaller than the risk associated with valproate in pregnancy.
"Anything is possible with focused strength, resilience and determination" said Bhavin Shah, Financial Director at Sigma Pharmaceuticals plc, after
completing the annual London Marathon.
Shah donned his running gear and completed the 26.2 mile route in a commendable time of 5 hours and 33 minutes, all in support of 'Team George', a cause
initiated by his close friend, Jonathan Bracey, who is the EVP of corporate development at Tanner Pharma Group.
Bracey started the crowdfunding initiative last year after his 2-year-old son George was diagnosed with a rare cancer (rhabdomyosarcoma) on his liver/bile duct.
Sigma Pharmaceuticals directors and staff have played a vital part in helping raise over £52,000 over the last 6 months for 'Team George', which included the
London Marathon Charity run on Sunday 21 April 2024. The funds will be donated to four charities that have been instrumental in George's path to overcoming
cancer - Rays of Sunshine ward at Kings College Hospital Charity, St Mary's Hospital, Alice's Arc and Great Ormond Street Hospital.
For over three months, Shah had been training himself physically and mentally for the marathon run to support his friend's initiative. He joined Bracey in the
marathon, along with more than 50,000 other competitors.
A groundbreaking study analysing data from nearly 600,000 cancer patients in England has shed light on the increased risk of second cancers among breast
cancer survivors.
The research conducted by University of Cambridge in association with the Lancet Regional Health-Europe studied data from over 580,000 female and over 3,500 male
breast cancer survivors diagnosed between 1995 and 2019 using the National Cancer Registration Dataset.
The findings suggest that survivors of breast cancer, the most prevalent cancer in the UK, face a substantially higher risk of developing second primary cancers.
According to the research, female survivors exhibited a twofold increase in the risk of contralateral breast cancer compared to the general population.
The data highlighted an 87 per cent greater risk of endometrial cancer, a 58 per cent greater risk of myeloid leukemia, and a 25 per cent greater risk of ovarian
cancer in female survivors.
Patients want to be active partners in their healthcare decisions - and eye care is no exception. Patient education is vital for understanding diagnoses,
treatment options, and the importance of preventative care. When patients understand what's happening with their health, they're far more likely to follow their
treatment plan and see good results. Here's a deeper look at why patient education matters.
Patient-Centered Care: The Key to Success
The Institute of Medicine emphasizes the importance of patient-centered care. This means involving patients in decision-making and providing them with the
necessary education for informed choices. This approach is even more crucial in eye care, where conditions can lead to irreversible blindness.
The Need for Patient Education
Research shows that many patients crave educational materials from their eye care providers, but many don't receive them. This leaves patients searching for
information on their own, potentially turning to unreliable sources. Clear, accessible patient education is vital in ensuring understanding and treatment
adherence.For instance, patient education is crucial in preventing diseases like glaucoma. The more informed patients are, the more chances they will
discover early signs of disease by taking OCT test for glaucoma.
In a new study, men who took phosphodiesterase type 5 inhibitors (PDE5Is), such as Viagra (sildenafil; Pfizer), for treatment of erectile dysfunction, were found to be 18 per cent less likely to develop Alzheimer's compared to those who did not take the drugs.
The results of the population-based cohort study were published in Neurology on 7 February 2024.
Researchers at University of Oxford examined IQVIA Medical Research Data UK records of 269,725 men, who were diagnosed with erectile dysfunction between
January 2000 and March 2017.
None of the participants had any memory or thinking problems at the start of the study and they were followed for an average of 5.1 years.
During the study, 749 out of 1,119 participants taking erectile dysfunction drugs developed Alzheimer's disease.
Thousands of cancer patients in England are set to gain fast-tracked access to personalised cancer vaccine trials through a new National Health Service(NHS)
initiative, the Cancer Vaccine Launch Pad.
This groundbreaking service aims to find new life-saving treatments by matching eligible patients with clinical trials across the country.
The first patient to receive a personalised vaccine for bowel cancer is Elliot Phebve, a 55-year-old lecturer, treated at University Hospitals Birmingham NHS
Foundation Trust.
Phebve, diagnosed through a routine health check, underwent surgery and chemotherapy before joining the trial.
Sponsored by German biotech company BioNTech SE, the colorectal cancer vaccine trial is one of several taking place across NHS trusts.
On World Head and Neck Cancer Day today (27 July), the National Health Service (NHS) has launched a new partnership with the British supermarket chain, Asda
to raise awareness of mouth cancer symptoms.
As part of this partnership, the NHS will provide vital advice on millions of toothpaste tubes and mouthwash bottles, urging people to consult their GP or dentist
if they notice any potential symptoms of mouth cancer.
Starting this month, the grocer's own brand of oral hygiene products will feature NHS advice in over 500 Asda stores nationwide.
The NHS guidance will be displayed on the packaging, along with a link to more detailed information about mouth and throat cancer on the health service website.
Professor Peter Johnson, national clinical director for cancer at NHS England, said: "Early detection of mouth cancer can help save lives and this fantastic new
partnership with Asda will be vital in raising awareness of the signs and in supporting the NHS's ambition to diagnose more cancers at an earlier stage.
Addiction is a complex and multifaceted condition that can significantly impact an individual's physical, emotional, and psychological well-being. Despite
the strong desire to overcome addiction, many people struggle to achieve lasting recovery on their own. Professional help is crucial in addiction treatment because
it offers specialized knowledge, comprehensive care, and evidence-based approaches tailored to each individual's needs. With the support of trained professionals,
individuals are more likely to develop the skills and strategies necessary to achieve and maintain long-term sobriety.
Understanding the Nature of Addiction
Addiction is often misunderstood as merely a lack of willpower or moral failing. However, it is recognized by the medical community as a chronic disease that
affects the brain's reward, motivation, and memory functions. These changes make it exceedingly challenging for individuals to control their substance use, even
when facing adverse consequences.
Through professional assessment, clinicians can identify the specific nature and extent of the addiction. This involves understanding the types of substances
used, frequency, and the presence of co-occurring mental health conditions. Accurate diagnosis is essential for developing a tailored treatment plan that addresses
all aspects of the individual's condition. The people behind https://healtreatmentcenters.com/resources/ note that there are many treatment centers and support
groups available to help people with addiction. It takes the expertise of professionals to properly diagnose and treat addiction effectively.
Hobbs, who joined the company in 2019, navigated it through the challenges of the COVID-19 pandemic, and successfully oversaw the acquisition and integration
of Lexon in 2023. He will retire from the company at the end of September 2024.
"After five years with the company, I am retiring at the end of September to spend time with my wife who was diagnosed with motor neurone disease last year," Hobbs
said.
"I wish to extend my personal thanks to our owners, the Bestway Group, for their kindness and understanding of our situation.
"It has been a privilege to lead the Well Pharmacy, now Bestway Healthcare organisation. The business is resilient for today and fit to prosper in the long term.
When I leave it will be with gratitude and admiration for the 7,500+ people in Bestway Healthcare who are committed to improving the lives of our patients and
customers, thank you all."